Hanmi Pharmaceutical
128940.KS · Bio
Korea's largest pharmaceutical company by revenue. Known for proprietary LAPSCOVERY long-acting platform technology, with multi-billion-dollar global licensing deals in obesity and diabetes therapeutics.
Latest news
Court Freezes 10 Billion Won of Hanmi Science Shares Held by Lim Ju-hyun
Hanmi Group Launches Company-Wide AI Innovation Program
Hanmi's Obesity Drug Plant Wins Top Safety Grade for Second Time
Kori Group's Beijing Hanmi Payables Double Ahead of Hong Kong Listing
Wegovy Falls 20-Fold Behind Mounjaro in New Prescriptions, May Cut Prices Again
Hanmi Pharm Shares Have Priced In Excessive Concerns, Analyst Says
Beijing Hanmi Faces Potential 100 Billion Won Receivables Loss, Testing CEO Hwang
Hanmi Science Q2 Operating Profit Jumps 71% on Subsidiary Growth, Distribution Gains
Hanmi Pharm Q2 Operating Profit Jumps 117% on Lilly Licensing Deal
Hanmi Pharmaceutical Advances AI-Designed Obesity Drug to US Trials
Korean Drugmakers Race for FDA Priority Review Vouchers Worth Billions
CNCure and Portrai Team Up on AI-Based Next-Generation Cancer Drugs
Hanmi Pharm to Improve Margins on Lilly Licensing, Sustain Growth With Domestic Obesity Drug
Hanmi's Melanoma Drug Belvarafenib Advances in Phase 2 Trial
Hanmi Pharm Q2 Earnings to Improve on Lilly Upfront Payment
Chairman Shin's 500 Billion Won Loan Signals Bid for Hanmi Science Control
Hanmi Science Rises 9% on Management Control Dispute Prospects
Shin Dong-kook Buys More Hanmi Science Shares, Narrows Gap to 5 Points
Bio Stocks Eye Revaluation Ahead of KOSDAQ Promotion-Relegation System
Hanmi Pharmaceutical Completes Acquisition of U.S. Biotech Aptose
Hanmi's Second Son Sides With Mother, Sells Stake to Now IB
Hanmi's Lim Jong-hoon Sells 2.5% Holding Company Stake
